Related Experiment Video
Updated: May 22, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
The evolving landscape of stage III unresectable non-small cell lung cancer "between lights and shadows"
Marco Donatello Delcuratolo1, Veronica Crespi2, Giorgio Saba3
1Medical Oncology Unit, Foundation IRCCS, Casa Sollievo Della Sofferenza, San Giovanni Rotondo, FG, Italy; Department of Oncology, University of Turin, AOU S. Luigi Gonzaga, Orbassano, TO, Italy.
Abstract:
Despite PACIFIC set a new milestone in the clinical management of unresectable stage III non-small cell lung cancer (NSCLC), it left some critical questions pending for clinical research: the efficacy of durvalumab in the real-world setting; the activity of less intensive regimens for frail populations; the role of targeted therapies in oncogene-addicted tumors; the selection of subsequent strategies at immunotherapy failure; the efficacy of novel and intensified treatments; the role of molecular biomarkers for patients' selection. This review aims to describe the evolving landscape of unresectable stage III NSCLC and provides an updated overview of the available evidence, analyzing lights and shadows emerging from recent clinical trials and discussing the most relevant challenges of post-PACIFIC era.
Insights
The PACIFIC trial advanced unresectable stage III non-small cell lung cancer (NSCLC) care. This review explores real-world durvalumab efficacy, novel treatments, and biomarkers for post-PACIFIC NSCLC management.
Area of Science:
- Oncology
- Thoracic Oncology
- Clinical Trials
Background:
- The PACIFIC trial established a new standard of care for unresectable stage III non-small cell lung cancer (NSCLC) with durvalumab consolidation therapy.
- Despite its success, significant clinical questions remain regarding optimal treatment strategies and patient selection in the post-PACIFIC era.
Purpose of the Study:
- To review the evolving treatment landscape for unresectable stage III NSCLC.
- To provide an updated overview of evidence from recent clinical trials.
- To discuss key challenges and future directions in the post-PACIFIC era.
Main Methods:
- Literature review of recent clinical trials and real-world data in unresectable stage III NSCLC.
- Analysis of treatment efficacy, patient populations, and emerging therapeutic strategies.
- Discussion of molecular biomarkers and immunotherapy failure management.
Main Results:
- Durvalumab demonstrates efficacy in real-world settings, but further research is needed for frail populations and less intensive regimens.
- Targeted therapies show promise in oncogene-addicted NSCLC, and strategies for immunotherapy failure are under investigation.
- Novel and intensified treatments are being explored, alongside the critical role of molecular biomarkers for patient selection.
Conclusions:
- The post-PACIFIC era requires a nuanced approach to unresectable stage III NSCLC management.
- Addressing real-world efficacy, specific patient subgroups, and biomarker-driven selection is crucial for optimizing outcomes.
- Continued research into novel therapies and subsequent treatment strategies is essential.
